Enliven Therapeutics
IPOSmall Molecule Kinase Inhibitors
Public · United States · $305.0M raised
- Business Model
- B2B
- Website
- enliventherapeutics.com
- Total Funding
- $305.0M
- Last Round
- $165.0M Corporate RoundFeb 2023
- Rounds
- 3
- Type
- Public
About
Clinical-stage biotech developing small molecule kinase inhibitors targeting BCR-ABL and HER2 for cancer treatment.
Summary
Enliven Therapeutics is a Biotech company based in United States. It has raised $305.0M in total across 3 rounds, most recently a $165.0M Corporate Round round in Feb 2023. Investors include OrbiMed and Fairmount.
Tech & App Stack
3 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2024
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company